Kevirx Inc.
Charlottesville, VA
- UEI
- UYB4K2ZUBD18
- CAGE
- 7PGF5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2218 Garth Rd, Charlottesville, VA 22901, USA
- Website
- kevirx.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Medchem Partners LLC | Lexington, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Proteogenomics Research Institute For Systems Medicine | San Diego, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Kevirx Inc. is a for-profit organization that has been registered in SAM.gov since August 2016 to receive federal grants and contracts. They primarily focus on developing small molecule inhibitors for various medical applications, including acute lung injury, COVID-19-related respiratory issues, and ovarian cancer.
Through recent federal grant awards, Kevirx Inc. has received funding from agencies such as the Defense Health Agency, the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute, and the NIH National Cancer Institute. In 2024, they secured a $1,991,213 project grant from the Defense Health Agency to develop KVX-053, a PTP4A3-targeted small molecule inhibitor, for the treatment of acute lung injury in military and battlefield settings. Additionally, in 2021, Kevirx Inc. received a $941,124 NIH grant to investigate the potential of KVX-053 in mitigating acute lung injury and cytokine storms associated with SARS-CoV-2 infection and COVID-19. Another NIH grant awarded in 2019, worth $289,307, supported their research on developing small molecule PTP4A3 inhibitors for ovarian cancer treatment. Across these grants, Kevirx Inc. has demonstrated expertise in developing targeted small molecule inhibitors for various medical applications, particularly in the areas of acute lung injury, respiratory diseases, and cancer therapeutics.
Quick answers
Is Kevirx Inc. registered in SAM.gov?
Yes. Kevirx Inc.'s SAM.gov registration is active through October 28, 2026.
What is Kevirx Inc.'s most recent federal award?
Kevirx Inc.'s most recent federal grant award is Developing KVX-053, a PTP4A3-targeted small molecule inhibitor, for acute lung injury (HT94252410284), from Defense Health Agency, on May 1, 2024.
On GovTribe
See Kevirx Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors